Randomised controlled trial (RCT) of community management of deep venous thrombosis (DVT) using low molecular weight heparin versus hospital care

Submission date	Recruitment status	Prospectively registered
23/01/2004	Stopped	☐ Protocol
Registration date	Overall study status	Statistical analysis plan
23/01/2004	Stopped	Results
Last Edited	Condition category	Individual participant data
18/04/2012	Circulatory System	Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr David Fitzmaurice

Contact details

Department of General Practice The Medical School University of Birmingham Edgbaston Birmingham United Kingdom B15 2TT +44 (0)121 414 3760 D.A.Fitzmaurice@bham.ac.uk

Additional identifiers

Protocol serial number

RGC00325

Study information

Scientific Title

Study objectives

Not provided at time of registration

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Study type(s)

Not Specified

Health condition(s) or problem(s) studied

Cardiovascular diseases: Thromboembolic disease

Interventions

Intervention patients will either be discharged from A&E following confirmation of diagnosis having been given the first dose of low-molecular weight heparin (LMWH) and warfarin, or prior to confirmation of diagnosis having received only the first dose of LMWH. Patients requiring confirmation of diagnosis will be recalled for special clinics established for the study.
 Control patients will be managed according to the hospital protocol. This normally requires admission for confirmation of diagnosis and commencement of formal anticoagulation with intra-venous heparin. The confirmatory investigation in all cases will be ultrasound.
 All patients with positive diagnosis of DVT will be recalled 4 weeks after the initial ultrasound for repeat investigation to determine the resolution of the clot and to complete a Quality of Life questionnaire.

As of 18/04/2012, this study was stopped due to poor recruitment in 1999.

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

heparin

Primary outcome(s)

Not provided at time of registration

Key secondary outcome(s))

Not provided at time of registration

Completion date

31/12/2000

Reason abandoned (if study stopped)

Participant recruitment issue

Eligibility

Key inclusion criteria

All patients aged 18 or over presenting to the A&E Department of the City Hospital, Birmingham, with a clinical diagnosis of Deep Venous Thrombosis (DVT) will be eligible for entry into the study. Patients will be randomised to either an intervention or control arm of the study. 484 patients will be recruited. Assuming a radiological positive diagnosis rate of 50% this will leave 121 patients in each arm of the study.

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

Not Specified

Key exclusion criteria

Patients who need to be admitted to hospital for concomitant reasons, patients requiring venography, pregnant and breast feeding women and patients with concurrent malignancy will be excluded.

Date of first enrolment

01/01/2000

Date of final enrolment

31/12/2000

Locations

Countries of recruitment

United Kingdom

Study participating centre
Department of General Practice
Birmingham
United Kingdom
B15 2TT

Sponsor information

Organisation

NHS R&D Regional Programme Register - Department of Health (UK)

Funder(s)

Funder type

Government

Funder Name

NHS Executive West Midlands (UK)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?

Participant information sheet Participant information sheet 11/11/2025 No Yes